PMID- 30071892
OWN - NLM
STAT- MEDLINE
DCOM- 20190514
LR  - 20240329
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 20
IP  - 1
DP  - 2018 Aug 2
TI  - Ten years of follow-up data in psoriatic arthritis: results based on standardized 
      monitoring of patients in an ordinary outpatient clinic in southern Norway.
PG  - 160
LID - 10.1186/s13075-018-1659-z [doi]
LID - 160
AB  - BACKGROUND: Over the last decade, a treat-to-target (T2T) strategy has been 
      recommended for psoriatic arthritis (PsA) and new treatment options have become 
      available. There is a lack of data on PsA regarding any changes that may have 
      occurred over these past years. Thus, the main aim of this study was to look for 
      changes in clinical disease status and treatment in a PsA outpatient clinic 
      population monitored over the period 2008 to 2017. METHODS: Annual data 
      collection included demographic data, laboratory (erythrocyte sedimentation rate 
      (ESR) and C-reactive protein (CRP)) and clinic measures of disease activity 
      (e.g., 28 and 32 joint count Disease Activity Score (DAS28), Clinical Disease 
      Activity Index (CDAI), and modified Disease Activity index for Psoriatic 
      arthritis (DAPSA)), evaluator's global assessment, and patient-reported outcomes 
      (PROs), including for example measures of physical function, pain, and patient 
      global assessment. Disease-modifying antirheumatic drug (DMARD) use was also 
      registered. RESULTS: In the PsA outpatient clinic population over the 10-year 
      period (annual mean number of patients, 331) the mean (standard deviation) age 
      was 58.4 (12.4) years, disease duration was 9.6 (7.9) years, 49.4% were female, 
      and 17.6% were current smokers. From 2008 to 2017, no statistically significant 
      increase in remission rates was seen for DAPSA (13.5% and 22.0%) or Boolean 
      remission (6.6% and 8.9%), whereas a statistically significant increase was seen 
      for DAS28-ESR (36.8% and 50.6%) and CDAI (20.0% and 29.6%), but not for the last 
      5 years (DAS28-ESR, 42.3% and 50.6%; CDAI, 27.9% and 29.6%). Furthermore, over 
      the 10-year period no significant improvement for PROs and no significant change 
      in the use of synthetic (annual mean 53.0%) and biologic DMARDs (annual mean 
      29.9%) was found. CONCLUSION: Our data suggest that even in the biologic 
      treatment era there is an unmet need for treating PsA patients to target 
      remission. New treatment options and the development of more feasible and valid 
      outcome measures for use in a T2T strategy in ordinary clinical practice may in 
      the future to further improve clinical outcomes in PsA.
FAU - Haugeberg, Glenn
AU  - Haugeberg G
AD  - Division of Rheumatology, Department of Medicine, Hospital of Southern Norway 
      Trust, Servicebox 416, 4604, Kristiansand, Norway. glenn.haugeberg@sshf.no.
AD  - Department of Neuroscience, Division of Rheumatology, Norwegian University of 
      Science and Technology, Trondheim, Norway. glenn.haugeberg@sshf.no.
FAU - Michelsen, Brigitte
AU  - Michelsen B
AD  - Division of Rheumatology, Department of Medicine, Hospital of Southern Norway 
      Trust, Servicebox 416, 4604, Kristiansand, Norway.
FAU - Tengesdal, Stig
AU  - Tengesdal S
AD  - Division of Rheumatology, Department of Medicine, Hospital of Southern Norway 
      Trust, Servicebox 416, 4604, Kristiansand, Norway.
FAU - Hansen, Inger Johanne Widding
AU  - Hansen IJW
AD  - Division of Rheumatology, Department of Medicine, Hospital of Southern Norway 
      Trust, Servicebox 416, 4604, Kristiansand, Norway.
FAU - Diamantopoulos, Andreas
AU  - Diamantopoulos A
AD  - Department of Rheumatology, Martina Hansens Hospital, Baerum, Norway.
FAU - Kavanaugh, Arthur
AU  - Kavanaugh A
AD  - Division of Rheumatology, Allergy, and Immunology, School of Medicine, University 
      of California, San Diego, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180802
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Antirheumatic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Ambulatory Care Facilities
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Psoriatic/*drug therapy/*pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Norway
MH  - Remission Induction
MH  - Treatment Outcome
PMC - PMC6090981
OTO - NOTNLM
OT  - Clinical outcome
OT  - Disease activity
OT  - Patient-reported outcome measures
OT  - Psoriatic arthritis
OT  - Real life registries
OT  - Treat to target
COIS- The approval for this study was given by the regional ethical committee (Regional 
      etisk komite Midt-Norge 2010/3078). No consent from patients was needed according 
      to the ethical committee, as all the data described above were collected as part 
      of clinical care to facilitate treatment decisions. Not applicable. GH is a 
      founder and shareholder for DiaGraphIT AS, manufacturing the GoTreatIT(R) Rheuma 
      software. The remaining authors declare that they have no competing interests. 
      Springer Nature remains neutral with regard to jurisdictional claims in published 
      maps and institutional affiliations.
EDAT- 2018/08/04 06:00
MHDA- 2019/05/15 06:00
PMCR- 2018/08/02
CRDT- 2018/08/04 06:00
PHST- 2018/05/22 00:00 [received]
PHST- 2018/07/04 00:00 [accepted]
PHST- 2018/08/04 06:00 [entrez]
PHST- 2018/08/04 06:00 [pubmed]
PHST- 2019/05/15 06:00 [medline]
PHST- 2018/08/02 00:00 [pmc-release]
AID - 10.1186/s13075-018-1659-z [pii]
AID - 1659 [pii]
AID - 10.1186/s13075-018-1659-z [doi]
PST - epublish
SO  - Arthritis Res Ther. 2018 Aug 2;20(1):160. doi: 10.1186/s13075-018-1659-z.